Loading stock data…
AnaptysBio, Inc. (ANAB)
$56.80-0.66 (-1.15%)
Pre-Market$55.35-1.45 (-2.55%)· Last close Sep 4
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AnaptysBio, Inc. in the Healthcare sector is trading at $56.80 with a market capitalization of $1.5B. Wall Street consensus targets $89.62 (8 analysts), implying a +57.8% move over the next 12 months. The stock is currently 22% below its 52-week high of $72.36, remaining 22.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +57.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $25.56M↓ | $108.25M↑ | $76.32M↑ | $22.26M↓ | $27.77M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$34.64M↓ | $66.90M↑ | $34.70M↑ | -$26.17M↑ | -$27.54M |
| Net Income | -$52.88M↓ | $49.61M↑ | $15.11M↑ | -$38.63M↑ | -$39.33M |
Peer Comparison
JNJUNHPFE
Fundamentals
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete wh...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.49B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-210.14%
Volume
Today's trading volume
1.06M
Recent News
GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, […]
CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of +11.54% and +7.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
What Makes AnaptysBio (ANAB) an Investment Bet?
Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment in Laughing Water Capital returning approximately 39.8% net of all fees and expenses, bringing the YTD return to approximately 33.6% net. […]
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.